Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARNT | P27540 | 5/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | PPOX | P50336 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296282 | 0.91 | MERTK (0.42) | ARNTEPAS1TDP1MEN1KMT2A | |
| SCHEMBL30296294 | 0.91 | MERTK (0.42) | ARNTEPAS1TDP1MEN1KMT2A | |
| SCHEMBL11007687 | 0.79 | PDE7A (0.60) | TDP1MEN1KMT2AHSPB1PDE7A | |
| SCHEMBL30296710 | 0.79 | MPO (0.38) | EPAS1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL137478 | 0.77 | TDP1 (0.38) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL30296550 | 0.77 | MPO (0.42) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL30051264 | 0.77 | KMT2A (0.40) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL30296504 | 0.74 | HTR2A (0.35) | EPAS1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL11017217 | 0.72 | PIN1 (0.44) | ARNTEPAS1MEN1KMT2AMERTK | |
| SCHEMBL9632914 | 0.72 | MERTK (0.49) | TDP1MEN1KMT2ATTRPPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | ARNT 143/4885EPAS1 1790/4885TDP1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.